E
Arch Therapeutics, Inc.
ARTH
$0.1574
-$0.0426-21.30%
E
Sell
3/27/2024Downgrade
Arch Therapeutics, Inc. (ARTH) was downgraded to E+ from D- on 3/27/2024 due to a decline in the volatility index, solvency index and valuation index. The quick ratio declined from 0.02 to 0.02.
Arch Therapeutics, Inc. (ARTH) was downgraded to E+ from D- on 3/27/2024 due to a decline in the volatility index, solvency index and valuation index. The quick ratio declined from 0.02 to 0.02.
D
Sell
11/22/2023Upgraded
Arch Therapeutics, Inc. (ARTH) was upgraded to D- from E+ on 11/22/2023 due to an increase in the volatility index and valuation index.
Arch Therapeutics, Inc. (ARTH) was upgraded to D- from E+ on 11/22/2023 due to an increase in the volatility index and valuation index.
E
Sell
3/14/2023Downgrade
Arch Therapeutics, Inc. (ARTH) was downgraded to E+ from D on 3/14/2023 due to a decline in the volatility index, total return index and solvency index. The quick ratio declined from 0.22 to 0, and debt to equity increased from -0.8 to -0.64.
Arch Therapeutics, Inc. (ARTH) was downgraded to E+ from D on 3/14/2023 due to a decline in the volatility index, total return index and solvency index. The quick ratio declined from 0.22 to 0, and debt to equity increased from -0.8 to -0.64.
D
Sell
2/1/2023Upgraded
Arch Therapeutics, Inc. (ARTHD) was upgraded to D from D- on 2/1/2023 due to an increase in the volatility index.
Arch Therapeutics, Inc. (ARTHD) was upgraded to D from D- on 2/1/2023 due to an increase in the volatility index.
D
Sell
1/5/2023Downgrade
Arch Therapeutics, Inc. (ARTH) was downgraded to D- from D on 1/5/2023 due to a large decline in the solvency index, growth index and total return index. Operating cash flow declined 190.63% from -$574.4 to -$1.67M, total revenue declined 74.6% from $6.3 to $1.6, and earnings per share declined from -$0.0044 to -$0.0076.
Arch Therapeutics, Inc. (ARTH) was downgraded to D- from D on 1/5/2023 due to a large decline in the solvency index, growth index and total return index. Operating cash flow declined 190.63% from -$574.4 to -$1.67M, total revenue declined 74.6% from $6.3 to $1.6, and earnings per share declined from -$0.0044 to -$0.0076.
D
Sell
5/16/2022Upgraded
Arch Therapeutics, Inc. (ARTH) was upgraded to D from E+ on 5/16/2022 due to an increase in the growth index and total return index. Earnings per share increased from -$0.0065 to -$0.0033, and operating cash flow increased 12.29% from -$1.18M to -$1.03M.
Arch Therapeutics, Inc. (ARTH) was upgraded to D from E+ on 5/16/2022 due to an increase in the growth index and total return index. Earnings per share increased from -$0.0065 to -$0.0033, and operating cash flow increased 12.29% from -$1.18M to -$1.03M.
E
Sell
5/13/2022Downgrade
Arch Therapeutics, Inc. (ARTH) was downgraded to E+ from D on 5/13/2022 due to a decline in the total return index.
Arch Therapeutics, Inc. (ARTH) was downgraded to E+ from D on 5/13/2022 due to a decline in the total return index.
D
Sell
5/4/2022Upgraded
Arch Therapeutics, Inc. (ARTH) was upgraded to D from E+ on 05/04/2022.
Arch Therapeutics, Inc. (ARTH) was upgraded to D from E+ on 05/04/2022.
E
Sell
5/1/2022Downgrade
Arch Therapeutics, Inc. (ARTH) was downgraded to E+ from D on 05/01/2022.
Arch Therapeutics, Inc. (ARTH) was downgraded to E+ from D on 05/01/2022.
D
Sell
4/21/2022Upgraded
Arch Therapeutics, Inc. (ARTH) was upgraded to D from E+ on 4/21/2022 due to an increase in the volatility index.
Arch Therapeutics, Inc. (ARTH) was upgraded to D from E+ on 4/21/2022 due to an increase in the volatility index.
E
Sell
4/20/2022Downgrade
Arch Therapeutics, Inc. (ARTH) was downgraded to E+ from D on 4/20/2022 due to a decline in the total return index and volatility index.
Arch Therapeutics, Inc. (ARTH) was downgraded to E+ from D on 4/20/2022 due to a decline in the total return index and volatility index.
D
Sell
2/11/2022Upgraded
Arch Therapeutics, Inc. (ARTH) was upgraded to D from D- on 2/11/2022 due to an increase in the valuation index, growth index and total return index. Total revenue increased 193.75% from $1.6 to $4.7, operating cash flow increased 22.09% from -$1.51M to -$1.18M, and EBIT increased 12.47% from -$1.72M to -$1.51M.
Arch Therapeutics, Inc. (ARTH) was upgraded to D from D- on 2/11/2022 due to an increase in the valuation index, growth index and total return index. Total revenue increased 193.75% from $1.6 to $4.7, operating cash flow increased 22.09% from -$1.51M to -$1.18M, and EBIT increased 12.47% from -$1.72M to -$1.51M.
D
Sell
11/3/2021Upgraded
Arch Therapeutics, Inc. (ARTH) was upgraded to D- from E+ on 11/3/2021 due to a noticeable increase in the growth index and total return index. Earnings per share increased from -$0.0084 to -$0.0065, and EBIT increased 4.72% from -$1.75M to -$1.67M.
Arch Therapeutics, Inc. (ARTH) was upgraded to D- from E+ on 11/3/2021 due to a noticeable increase in the growth index and total return index. Earnings per share increased from -$0.0084 to -$0.0065, and EBIT increased 4.72% from -$1.75M to -$1.67M.
E
Sell
7/16/2021Downgrade
Arch Therapeutics, Inc. (ARTH) was downgraded to E+ from D- on 7/16/2021 due to a decline in the total return index and volatility index.
Arch Therapeutics, Inc. (ARTH) was downgraded to E+ from D- on 7/16/2021 due to a decline in the total return index and volatility index.
D
Sell
7/1/2021Upgraded
Arch Therapeutics, Inc. (ARTH) was upgraded to D- from E+ on 7/1/2021 due to an increase in the volatility index and valuation index.
Arch Therapeutics, Inc. (ARTH) was upgraded to D- from E+ on 7/1/2021 due to an increase in the volatility index and valuation index.
E
Sell
6/8/2021Downgrade
Arch Therapeutics, Inc. (ARTH) was downgraded to E+ from D- on 6/8/2021 due to a decline in the total return index and volatility index.
Arch Therapeutics, Inc. (ARTH) was downgraded to E+ from D- on 6/8/2021 due to a decline in the total return index and volatility index.
D
Sell
5/24/2021Downgrade
Arch Therapeutics, Inc. (ARTH) was downgraded to D- from D on 5/24/2021 due to a large decline in the efficiency index, growth index and valuation index. Earnings per share declined from -$0.006 to -$0.01, net income declined 55.21% from -$1.15M to -$1.79M, and EBIT declined 41.86% from -$1.23M to -$1.75M.
Arch Therapeutics, Inc. (ARTH) was downgraded to D- from D on 5/24/2021 due to a large decline in the efficiency index, growth index and valuation index. Earnings per share declined from -$0.006 to -$0.01, net income declined 55.21% from -$1.15M to -$1.79M, and EBIT declined 41.86% from -$1.23M to -$1.75M.
D
Sell
4/30/2020Upgraded
Arch Therapeutics, Inc. (ARTH) was upgraded to D from D- on 4/30/2020 due to an increase in the volatility index.
Arch Therapeutics, Inc. (ARTH) was upgraded to D from D- on 4/30/2020 due to an increase in the volatility index.
D
Sell
4/13/2020Downgrade
Arch Therapeutics, Inc. (ARTH) was downgraded to D- from D on 4/13/2020 due to a decline in the total return index, volatility index and valuation index.
Arch Therapeutics, Inc. (ARTH) was downgraded to D- from D on 4/13/2020 due to a decline in the total return index, volatility index and valuation index.
D
Sell
3/24/2020Upgraded
Arch Therapeutics, Inc. (ARTH) was upgraded to D from D- on 3/24/2020 due to an increase in the volatility index and valuation index.
Arch Therapeutics, Inc. (ARTH) was upgraded to D from D- on 3/24/2020 due to an increase in the volatility index and valuation index.
D
Sell
3/6/2020Downgrade
Arch Therapeutics, Inc. (ARTH) was downgraded to D- from D on 3/6/2020 due to a decline in the volatility index and total return index.
Arch Therapeutics, Inc. (ARTH) was downgraded to D- from D on 3/6/2020 due to a decline in the volatility index and total return index.
D
Sell
2/19/2020Upgraded
Arch Therapeutics, Inc. (ARTH) was upgraded to D from D- on 2/19/2020 due to an increase in the total return index and valuation index.
Arch Therapeutics, Inc. (ARTH) was upgraded to D from D- on 2/19/2020 due to an increase in the total return index and valuation index.
D
Sell
2/4/2020Downgrade
Arch Therapeutics, Inc. (ARTH) was downgraded to D- from D+ on 2/4/2020 due to a significant decline in the efficiency index, growth index and valuation index. Net income declined 100.43% from -$828.1 to -$1.66M, earnings per share declined from -$0.0048 to -$0.009, and operating cash flow declined 34.79% from -$980.5 to -$1.32M.
Arch Therapeutics, Inc. (ARTH) was downgraded to D- from D+ on 2/4/2020 due to a significant decline in the efficiency index, growth index and valuation index. Net income declined 100.43% from -$828.1 to -$1.66M, earnings per share declined from -$0.0048 to -$0.009, and operating cash flow declined 34.79% from -$980.5 to -$1.32M.
D
Sell
11/20/2019Upgraded
Arch Therapeutics, Inc. (ARTH) was upgraded to D+ from D on 11/20/2019 due to a noticeable increase in the growth index and valuation index. Operating cash flow increased 36.51% from -$1.54M to -$980.5, earnings per share increased from -$0.0077 to -$0.0074, and EBIT increased 3.05% from -$1.57M to -$1.52M.
Arch Therapeutics, Inc. (ARTH) was upgraded to D+ from D on 11/20/2019 due to a noticeable increase in the growth index and valuation index. Operating cash flow increased 36.51% from -$1.54M to -$980.5, earnings per share increased from -$0.0077 to -$0.0074, and EBIT increased 3.05% from -$1.57M to -$1.52M.
D
Sell
11/12/2019Downgrade
Arch Therapeutics, Inc. (ARTH) was downgraded to D from D+ on 11/12/2019 due to a major decline in the total return index and volatility index.
Arch Therapeutics, Inc. (ARTH) was downgraded to D from D+ on 11/12/2019 due to a major decline in the total return index and volatility index.
D
Sell
3/29/2019Downgrade
Arch Therapeutics, Inc. (ARTH) was downgraded to D+ from C- on 3/29/2019 due to a decline in the volatility index and total return index.
Arch Therapeutics, Inc. (ARTH) was downgraded to D+ from C- on 3/29/2019 due to a decline in the volatility index and total return index.
C
Hold
3/14/2019Upgraded
Arch Therapeutics, Inc. (ARTH) was upgraded to C- from D+ on 3/14/2019 due to an increase in the total return index and volatility index.
Arch Therapeutics, Inc. (ARTH) was upgraded to C- from D+ on 3/14/2019 due to an increase in the total return index and volatility index.
D
Sell
2/21/2019Downgrade
Arch Therapeutics, Inc. (ARTH) was downgraded to D+ from C- on 2/21/2019 due to a decline in the total return index.
Arch Therapeutics, Inc. (ARTH) was downgraded to D+ from C- on 2/21/2019 due to a decline in the total return index.
C
Hold
2/4/2019Upgraded
Arch Therapeutics, Inc. (ARTH) was upgraded to C- from D+ on 2/4/2019 due to an increase in the total return index.
Arch Therapeutics, Inc. (ARTH) was upgraded to C- from D+ on 2/4/2019 due to an increase in the total return index.
D
Sell
2/1/2019Upgraded
Arch Therapeutics, Inc. (ARTH) was upgraded to D+ from D- on 2/1/2019 due to a significant increase in the efficiency index, valuation index and growth index. Operating cash flow increased 27.58% from -$1.83M to -$1.32M, and EBIT increased 20.85% from -$2.23M to -$1.77M.
Arch Therapeutics, Inc. (ARTH) was upgraded to D+ from D- on 2/1/2019 due to a significant increase in the efficiency index, valuation index and growth index. Operating cash flow increased 27.58% from -$1.83M to -$1.32M, and EBIT increased 20.85% from -$2.23M to -$1.77M.
D
Sell
6/22/2018Upgraded
Arch Therapeutics, Inc. (ARTH) was upgraded to D- from E+ on 6/22/2018 due to an increase in the volatility index.
Arch Therapeutics, Inc. (ARTH) was upgraded to D- from E+ on 6/22/2018 due to an increase in the volatility index.
E
Sell
4/30/2018Downgrade
Arch Therapeutics, Inc. (ARTH) was downgraded to E+ from D- on 4/30/2018 due to a noticeable decline in the growth index, volatility index and total return index. Earnings per share declined from $0.0024 to -$0.0103, operating cash flow declined 43.59% from -$1.1M to -$1.57M, and EBIT declined 27.26% from -$1.58M to -$2.01M.
Arch Therapeutics, Inc. (ARTH) was downgraded to E+ from D- on 4/30/2018 due to a noticeable decline in the growth index, volatility index and total return index. Earnings per share declined from $0.0024 to -$0.0103, operating cash flow declined 43.59% from -$1.1M to -$1.57M, and EBIT declined 27.26% from -$1.58M to -$2.01M.
D
Sell
7/28/2017Downgrade
Arch Therapeutics, Inc. (ARTH) was downgraded to D- from D on 7/28/2017 due to a decline in the efficiency index, growth index and total return index. Total capital declined 26.15% from $4.58M to $3.38M.
Arch Therapeutics, Inc. (ARTH) was downgraded to D- from D on 7/28/2017 due to a decline in the efficiency index, growth index and total return index. Total capital declined 26.15% from $4.58M to $3.38M.
D
Sell
3/15/2017Downgrade
Arch Therapeutics, Inc. (ARTH) was downgraded to D from D+ on 3/15/2017 due to a major decline in the total return index.
Arch Therapeutics, Inc. (ARTH) was downgraded to D from D+ on 3/15/2017 due to a major decline in the total return index.
D
Sell
2/8/2017Upgraded
Arch Therapeutics, Inc. (ARTH) was upgraded to D+ from D on 2/8/2017 due to a substantial increase in the total return index.
Arch Therapeutics, Inc. (ARTH) was upgraded to D+ from D on 2/8/2017 due to a substantial increase in the total return index.
D
Sell
2/2/2017Upgraded
Arch Therapeutics, Inc. (ARTH) was upgraded to D from D- on 2/2/2017 due to a major increase in the growth index, efficiency index and volatility index. EBIT increased 22.87% from -$1.78M to -$1.38M, net income increased 22.86% from -$1.82M to -$1.4M, and earnings per share increased from -$0.0124 to -$0.0104.
Arch Therapeutics, Inc. (ARTH) was upgraded to D from D- on 2/2/2017 due to a major increase in the growth index, efficiency index and volatility index. EBIT increased 22.87% from -$1.78M to -$1.38M, net income increased 22.86% from -$1.82M to -$1.4M, and earnings per share increased from -$0.0124 to -$0.0104.
D
Sell
7/29/2016Upgraded
Arch Therapeutics, Inc. (ARTH) was upgraded to D- from E+ on 7/29/2016 due to a substantial increase in the solvency index, total return index and valuation index. The quick ratio increased from 4.18 to 8.42, and debt to equity declined from 9.13 to 0.25.
Arch Therapeutics, Inc. (ARTH) was upgraded to D- from E+ on 7/29/2016 due to a substantial increase in the solvency index, total return index and valuation index. The quick ratio increased from 4.18 to 8.42, and debt to equity declined from 9.13 to 0.25.
E
Sell
4/28/2016Downgrade
Arch Therapeutics, Inc. (ARTH) was downgraded to E+ from D on 4/28/2016 due to a major decline in the solvency index, growth index and volatility index. Debt to equity increased from 1.36 to 9.13, earnings per share declined from -$0.0106 to -$0.0114, and operating cash flow declined 3.63% from -$1.14M to -$1.19M.
Arch Therapeutics, Inc. (ARTH) was downgraded to E+ from D on 4/28/2016 due to a major decline in the solvency index, growth index and volatility index. Debt to equity increased from 1.36 to 9.13, earnings per share declined from -$0.0106 to -$0.0114, and operating cash flow declined 3.63% from -$1.14M to -$1.19M.
D
Sell
12/11/2015Downgrade
Arch Therapeutics, Inc. (ARTH) was downgraded to D from D+ on 12/11/2015 due to a noticeable decline in the efficiency index, total return index and valuation index. Total capital declined 164.76% from -$4.6M to $2.98M, and net income declined 21.34% from -$1.4M to -$1.1M.
Arch Therapeutics, Inc. (ARTH) was downgraded to D from D+ on 12/11/2015 due to a noticeable decline in the efficiency index, total return index and valuation index. Total capital declined 164.76% from -$4.6M to $2.98M, and net income declined 21.34% from -$1.4M to -$1.1M.
D
Sell
9/22/2015Downgrade
Arch Therapeutics, Inc. (ARTH) was downgraded to D+ from C- on 9/22/2015 due to a decline in the volatility index and valuation index.
Arch Therapeutics, Inc. (ARTH) was downgraded to D+ from C- on 9/22/2015 due to a decline in the volatility index and valuation index.
C
Hold
8/25/2015Upgraded
Arch Therapeutics, Inc. (ARTH) was upgraded to C- from D+ on 8/25/2015 due to an increase in the total return index and valuation index.
Arch Therapeutics, Inc. (ARTH) was upgraded to C- from D+ on 8/25/2015 due to an increase in the total return index and valuation index.
D
Sell
8/7/2015Downgrade
Arch Therapeutics, Inc. (ARTH) was downgraded to D+ from C on 8/7/2015 due to a substantial decline in the efficiency index and valuation index.
Arch Therapeutics, Inc. (ARTH) was downgraded to D+ from C on 8/7/2015 due to a substantial decline in the efficiency index and valuation index.
C
Hold
7/16/2015Upgraded
Arch Therapeutics, Inc. (ARTH) was upgraded to C from C- on 7/16/2015 due to a noticeable increase in the volatility index and total return index.
Arch Therapeutics, Inc. (ARTH) was upgraded to C from C- on 7/16/2015 due to a noticeable increase in the volatility index and total return index.
C
Hold
5/8/2015Upgraded
Arch Therapeutics, Inc. (ARTH) was upgraded to C- from D on 5/8/2015 due to a major increase in the valuation index, growth index and total return index. Operating cash flow increased 12.73% from -$850.8 to -$959.1.
Arch Therapeutics, Inc. (ARTH) was upgraded to C- from D on 5/8/2015 due to a major increase in the valuation index, growth index and total return index. Operating cash flow increased 12.73% from -$850.8 to -$959.1.
D
Sell
7/1/2014Upgraded
Arch Therapeutics, Inc. (ARTH) was upgraded to D from D- on 7/1/2014 due to a significant increase in the efficiency index, solvency index and valuation index. Net income increased 936.64% from -$808.4 to -$8.38M, and debt to equity declined from -1.93 to -0.11.
Arch Therapeutics, Inc. (ARTH) was upgraded to D from D- on 7/1/2014 due to a significant increase in the efficiency index, solvency index and valuation index. Net income increased 936.64% from -$808.4 to -$8.38M, and debt to equity declined from -1.93 to -0.11.
D
Sell
3/3/2014Upgraded
Arch Therapeutics, Inc. (ARTH) was upgraded to D- from E+ on 3/3/2014 due to an increase in growth, total return and solvency.
Arch Therapeutics, Inc. (ARTH) was upgraded to D- from E+ on 3/3/2014 due to an increase in growth, total return and solvency.
OTC PK
04/11/2025 9:48AM Eastern
Quotes delayed
